Twenty-eight (43%) patients had refractory neuroblastoma, and 37 (57%) had relapsed neuroblastoma; 51 (78.5%) had measurable disease, and 14 (21.5%) had evaluable disease; 19 (29%) had MYCN amplification; 24 (37%) had received previous anti-GD2. This evidence concerns the gene MYCN and neuroblastoma.